17
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

New compounds for the treatment of eczematous skin diseases

Pages 1023-1033 | Published online: 25 Feb 2005

Bibliography

  • FRIEDMANN PS: Allergy and the skin. II- Contact and atopic eczema. Br Med. .1 (1998) 316:1226–1229.
  • •Gives a good introduction into the field and a nice overview.
  • LEUNG D Y, SOTER NA: Cellular and immunologic mechanisms in atopic dermatitis. j Am. Acad. Dermatal (2001) 44:S1–S12.
  • •Excellent review with recent immunologicalfindings.
  • CHARMAN C: Clinical evidence: atopic eczema. Br Med. J. (1999) 318:1600–1604.
  • BELTRANI VS: The clinical spectrum of atopic dermatitis. j Allergy Clin. Immoral (1999) 104:S87–98.
  • GREWE M, BRUIJNZEEL- KOOMENCA, SCHOPF E et al.: A role for Thl and Th2 cells in the immunopathogenesis of atopic dermatitis. Immoral. Today (1998) 19:359–361.
  • ••Excellent review with recent immunologicalfindings.
  • GIROLOMONI G, SEBASTIANI S, ALBANESI C et al: T cell subpopulations in the development of atopic and contact allergy. Curr. Opin. Immoral. (2001) 13:733–737.
  • ••Excellent review with recent immunologicalfindings.
  • CAVANI A, ALBANESI C, TRAIDL C et al.: Effector and regulatory T cells in allergic contact dermatitis. Trends Immoral (2001) 22:118–120.
  • •Gives a good introduction into the field and a nice overview.
  • GIROLOMONI G, PASTORE S: The role of keratinocytes in the pathogenesis of atopic dermatitis. j Am. Acad. Dermatal (2001) 45(1):S25–28.
  • ALBANESI C, SCARPONI C, SEBASTIANI S et al.: A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Thl cell accumulation in chronic inflammatory skin diseases. Leukocyte Biol. (2001) 70:617–623.
  • SEBASTIANI S, ALLAVENA E ALBANESI C et al: Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. Immoral. (2001) 166:996–1002.
  • AKDIS CA, AKDIS M, SIMON HU, BLASER K: Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int. Arch. Allergy Immune]. (1999) 118:140–144.
  • ••Excellent review with recent immunologicalfindings.
  • ASSMANN T, HOMEY B, RUZICKA T: Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin. Pharmacother. (2001) 7:1167–1175.
  • •Gives a good introduction into the field and a nice overview.
  • WOLLENBERG A, BIEBER T: Topical immunomodulatory agents and their targets in inflammatory skin diseases. Transplant Proc. (2001) 33:2212–2216.
  • •Gives a good introduction into the field and a nice overview.
  • FLEISCHER AB JR: Treatment of atopicdermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. j Allergy Clin. Ioannina (1999) 104:S126–130.
  • SOWDEN JM, BERTH-JONES J, ROSS JS et al.: Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet (1991) 338:137–140.
  • MEGGITT SJ, REYNOLDS NJ: Azathioprine for atopic dermatitis. Clin. Exp. Dermatal (2001) 26:369–375.
  • BUCKLEY DA, BALDWIN P, ROGERS S: The use of azathioprine in severe adult atopic eczema. j Eur. Acad. Dermatal. Venereal (1998) 11:137–140.
  • GRUNDMANN-KOLLMANN M, KAUFMANN R, ZOLLNER TM: Treatment of atopic dermatitis with mycophenolate mofetil. Br j Dermatal. (2001) 145:351–352.
  • BENEZ A, FIERLBECK G: Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br. Dermatal (2001) 144:638–639.
  • •Relevant clinical study.
  • BEKERSKY I, FITZSIMMONS W, TANASE A et al.: Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. j Am. Acad. Dermatal. (2001) 44:S17–27.
  • SOTER NA, FLEISCHER AB Jr., WEBSTER GF etal.: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J. Am. Acad. Dermatal. (2001) 44:S39–46.
  • •Relevant clinical study.
  • GRASSBERGER M, BAUMRUKER T, ENZ A et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br. Dermatal. (1999) 141:264–273.
  • LUGER T, VAN LEENT EJ, GRAEBER M et al: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br Dermatal (2001) 144:788–794.
  • •Gives a good introduction into the field and a nice overview.
  • HARPER J, GREEN A, SCOTT G et al: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. Dermatal. (2001) 144:781–787.
  • TUDAN C, JACKSON JK, PELECH SL, ATTARDO G, BURT H: Selective inhibition of protein kinase C, mitogen-activated protein kinase and neutrophil activation in response to calcium pyrophosphate dihydrate crystals, formyl-methionyl-leucyl-phenylalanine and porbal esters by O-(chloroacetyl-carbamoyff fumagillol. Biochem. Pharmacal (1999) 58:1869–1880.
  • LEONARD W J: Role of Jak kinases and S TATs in cytokine signal transduction. Int. Hematal. (2001) 73:271–277.
  • MESSER G, RUPEC RA: Nuclear factor ic B (NF-0). II. Pathophysiologic meaning. Hautarzt (2001) 52:746–752.
  • ASADULLAH K, DOCKE WD, SABAT RV et al: The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin Investig. Drugs (2000) 9(1):95–102.
  • CORINTI S, ALBANESI C, LA-SALA A et al.: Regulatory activity of autocrine IL-10 on dendritic cell functions. j Immoral. (2001) 166:4312–4318.
  • MACKIE R: Interferon-a for atopic dermatitis. Lancet (1990) 335:1282–1283.
  • REINHOLD U, WEHRMANN W, KUKEL S etal.: Recombinant interferon-y in severe atopic dermatitis. Lancet (1990) 335:1282.
  • KAGI MK, HEYER G: Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br Dermatal. (2001) 145:350–351.
  • CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357:1842–1847.
  • •Relevant clinical study.
  • RUCKERT R, ASADULLAH K, SEIFERT M etal.: Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? j Immuriol. (2000) 165:2240–2250.
  • ELLIS CN, KRUEGER GG: Treatment of chronic plague psoriasis by selective targeting of memory effector T lymphocytes. N Eng. j Med. (2001) 345:248–255.
  • PAPP K, BISSONNETTE R, KRUEGER JG etal.: The treatment of moderate-to-severe psoriasis with a new anti-CD 1 la monoclonal antibody. I Am. Acad. Dermatol. (2001) 45:665–674.
  • BHUSHAN M, BLEIKER TO, BALLSDON AE et al.: AntiE-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br j Dermatol. (2002) 146:824–831.
  • GOODMAN DS: Vitamin A and retinoids in health and disease. N ErigL j Med. (1984) 310:1023–1031.
  • FAHLMAN C, JACOBSEN SE, SMELAND EB et al.: All-trans and 9-cls-retinoic acid inhibit growth of normal human and murine B cell precursors. Immuriol (1995) 155:58–64.
  • WORM M, KRAH JM, MANZ R et al.: Retinoic acid inhibits CD4O+IL-4 mediated IgE-production in vitro. Blood (1998) 92: 1713-1719.
  • LEMIRE JM: 1,25-Dihydroxyvitamin D3 - a hormone with immunomodulatory properties. Z Rheumatol. (2000) 59(1):24–27.
  • ••Excellent review with recentimmunological findings.
  • MULLER KM. DIAMANT K. BENDTZEN: Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Itrimuriol. Lett. (1991) 28:115–120.
  • PRO VVEDINI DM, TSOUKAS CD. DEFTOS LJ et al.: 1 a,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. Immuriol. (1986) 136:2734–2740.
  • CARLBERG C: Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling. Eur. Biochem. (1995) 231:517–527.
  • •Gives a good introduction into the field and a nice overview.
  • CLARK RB, BISHOP-BAILEY D, ESTRADA-HERNANDEZ T et al.: The nuclear receptor PPAR y and immunoregulation: PPAR y mediates inhibition of helper T cell responses. Immuriol. (2000) 164:1364–1371.
  • KERSTEN S, DESVERGNE B, WAHLI W: Roles of PPARs in health and disease. Nature (2000) 405:421–424.
  • ••Excellent review with recentimmunological findings.
  • CAPELLA GL, GRIGERIO E, ALTOMARE G: A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur. Dermatol. (2001) 11:209–213.
  • •Relevant clinical study.
  • TASKAPAN MO: Zileuton and atopic dermatitis. Ann. Allergy Asthma Immunol. (2001) 87:162–163.
  • BERENDSEN HH, BROEKKAMP CL: Age dependence of 5-methoxytryptamine-induced hindlimb scratching in rats. Eur. Pharmacol. (1991) 199:107–109.
  • SERUP J: Allergic contact dermatitis from retinoic acid. Contact Dermatitis (1995) 33:142.
  • HEIDENHEIM M, JEMEC GB: Occupational allergic contact dermatitis from vitamin A acetate. Contact Dermatitis (1995) 33:439.
  • GIORDANO-LABADIE F, LAPLANCHE G, BAZEX J: Contact eczema caused by calcipotriol. Ann. Dermatol. Venereal. (1996) 123:196–197.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.